Paracelsus-Kliniken Deutschland GmbH & Co. KGaA — Clinical Trial Site

10 Registered trials

5 Currently recruiting

Organisation

Paracelsus-Kliniken Deutschland GmbH & Co. KGaA

Location

Kassel, Germany

Identifier

ORG-100043280

Address

Winkelhausenstraße 22, Hafen, 49090, Germany

Departments

Center for Parkinson's Disease and Movement Disorder
Center for Parkinson's Disease and Movement Disorders
Center for Parkinson’s Disease and Movement Disorders
Center for Parkinsons Disease and Movement Disorder
Elena-Klinik Kassel
Klinik für Neurologie
N/A
Studienabteilung
Zentrum f. Parkinson Syndrome und Bewegungsstörungen
Zentrum für Parkinson-Syndrome und Bewegungsstoerungen

Clinical trials at this site (10)

Search interface

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending

2025-521113-13-00 Early Parkinson’s Disease 10
An Open-Label Extension, Multi-Centered, Phase 2 Trial of TEV-56286 (Emrusolmin) for Multiple System Atrophy Recruiting

2025-521642-14-00 Multiple System Atrophy 4 2026-03-05
A Study to Compare the Efficacy and Safety of Prasinezumab with a placebo in Participants with Early-Stage Parkinson’s Disease Recruiting

2025-522683-32-00 Early-Stage Parkinson’s Disease (PD) 5 2026-01-15
A Multi-centered, Double-blind, Randomized, Placebo-controlled Study of TEV-56286 for the Treatment of Multiple System Atrophy Recruiting

2023-505320-54-00 Multiple System Atrophy 4 2025-01-30
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease (PASADENA) Recruiting

2023-504472-24-00 Early Idiopathic Parkinson’s disease (PD) 4 2024-03-19
An adaptive, Phase 2, double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety, tolerability, immunogenicity, … Recruiting

2022-500292-31-00 Early stages of idiopathic Parkinson's Disease 4 2023-05-12
AMX0035 and Progressive Supranuclear Palsy Ended

2023-505893-14-00 Progressive Supranuclear Palsy 5 2024-06-04
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD (ACTIVATE study) Ended

2022-501783-18-00 Parkinson’s Disease 4 2023-07-21
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants … Ended

2023-505645-12-00 Parkinson's Disease 4 2022-11-28
A Study to evaluate Efficacy, Safety, Tolerability and Effects of TAK-341 in the human body in patients with Multiple System Atrophy Ended

2023-509876-40-00 Multiple System Atrophy 4 2022-11-22